IP Library Granted Patent US 9,205,145
Granted Patent B2
US 9,205,145 · App. 12/744,136 · Granted Dec 8, 2015

Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,205,145
App. No.
12/744,136
Granted
Dec 8, 2015
Kind
B2
Abstract

Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or ameliorating infection of ruminants with Bluetongue virus. Administration to an animal of at least one dose of an adjuvanted and twice inactivated Bluetongue virus composition as disclosed herein is effective in providing immunity to the animal and protection from infection with Bluetongue virus, thereby reducing the severity of and/or preventing disease caused by one or more strains or serotypes of Bluetongue virus.

Claims (13)

1. A method of producing inactivated whole Bluetongue virus (BTV) that protects animals from viremia, the method comprising the steps of:

a) treating the BTV with an inactivating agent using a 1:10 ratio of inactivating agent to BTV, while the BTV remains in a complete culture;

b) homogenizing the inactivating agent/BTV mixture of step a) for at least 15 minutes;

c) decanting the mixture of step b) into a container and agitating the mixture for about 24 hours;

d) treating the agitated mixture resultant from step c) with an inactivating agent using a 1:20 ratio of inactivating agent to BTV therein;

e) homogenizing the inactivating agent/BTV mixture of step d) for at least 15 minutes;

f) decanting the mixture of step e) into a container and agitating the mixture for about 48 hours; and

g) neutralizing the inactivating agent, and adjusting the final pH to about 7.2, if needed;

wherein the method results in inactivation of the BTV while maintaining the immunogenicity of the BTV.

2. The method of claim 1 , wherein the inactivating agent is binary ethyleneimine (BEI).

3. The method of claim 1 , wherein the final concentration of inactivating agent in step a) is about 10 mM.

4. The method of claim 1 , wherein the final concentration of inactivating agent in step d) is about 5 mM.

5. The method of claim 1 , wherein the whole Bluetongue virus is serotype 4.

Assignments (5)
ADDRESS CHANGE OF ASSIGNEE Recorded Jun 5, 2017
From: ZOETIS SERVICES LLC
To: ZOETIS SERVICES LLC
Reel/Frame 042687/0541 →
MERGER Recorded May 13, 2015
From: ZOETIS P&U LLC
To: ZOETIS SERVICES LLC
Reel/Frame 035623/0700 →
CHANGE OF NAME Recorded Aug 25, 2014
From: PAH P&U LLC
To: ZOETIS P&U LLC
Reel/Frame 033605/0714 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2014
From: WYETH FARMA, S.A.
To: PAH P&U LLC
Reel/Frame 033588/0981 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2014
From: DURAN, JOAN PLANA
To: ZOETIS P&U LLC
Reel/Frame 033229/0408 →